You are here

Enhancing the Experience of Endocrine Therapy Study

Researcher
Annette Stanton, PhD, University of California Los Angeles, Los Angeles, CA
Study abstract

Current guidelines recommend at least five years of tamoxifen or aromatase inhibitors after primary treatment for hormone receptor-positive breast cancer. Nonadherence (ie, failing to take the medication as prescribed) and nonpersistence (ie, discontinuing the medication prior to the prescribed duration) with endocrine therapy are common.

The primary goal of this study is to provide a pilot test of brief videos designed to promote adherence to endocrine therapy.

Study review

Research shows that although some women do take their endocrine therapy daily, others do not take it regularly, stop taking it, or decide to switch to another type of endocrine therapy. The primary goal of this study was pilot test short videos designed to promote adherence to endocrine therapy. The researchers wanted to enroll up to 500 volunteers and used the Army of Women (AOW) as one of their recruitment sources. The Call to Action for this study was sent to AOW members on December 8, 2015. The researchers closed enrollment on March 28, 2016. Through the AOW, the research team identified 601 women who were interested in enrolling in the study. The research team published the study results in Breast Cancer Research and Treatment.

Resulting Publications:
Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.